-
Sep 7, 2025
Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints
>JS005 has achieved positive results in a multi-center, randomized, double-blind, parallel, placebo-controlled pivotal registrational Phase 3 clinical study for the treatment of moderate to severe plaque psoriasis
View details -
Aug 8, 2025
Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma
>The sNDA for toripalimab in combination with disitamab vedotin as the treatment of HER2-expressing locally advanced or metastatic UC has been accepted by the NMPA.
View details -
May 27, 2025
Junshi Biosciences Announces Ongericimab’s sNDA Approval in China
>The NMPA has recently approved ongericimab's two sNDA, becoming China’s first domestic PCSK9-targeted drug approved for statin-intolerant patients
View details -
Apr 25, 2025
Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma
>This marks the approval of toripalimab’s 12th indication in the Chinese mainland.
View details